The benefit of adjuvant chemotherapy (AC) for ampullary adenocarcinoma is unclear.
The Hidden Genome model classifies prognostic subtypes with greater accuracy than standard histologic classification (intestinal [INT] vs pancreatobiliary [PB]), but its predictive capacity to guide the use of AC remains unstudied.
